Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.

Theranostics - 1 Jan 2020

Song Xiangping, Shen Lin, Tong Jingshan, Kuang Chaoyuan, Zeng Shan, Schoen Robert E, Yu Jian, Pei Haiping, Zhang Lin

Abstract excerpt

Intrinsic and acquired resistance to targeted therapies is a significant clinical problem in cancer. We previously showed that resistance to regorafenib, a multi-kinase inhibitor for treating colorectal cancer (CRC) patients, can be caused by mutations in the tumor suppressor FBW7, which block degradation of the pro-survival Bcl-2 family protein Mcl-1. We tested if Mcl-1 inhibition can be used to develop a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to F-Box-WD Repeat-Containing Protein 7

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knock-In Techniques

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Organoids

Share to Phenylurea Compounds

Share to Primary Cell Culture

Share to Thiophenes

Source

Open in PubMed Open full text

Identifiers

PMID: 32724460
DOI: 10.7150/thno.45363
PMCID: PMC7381732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.PMID 32724460Read ↗

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal CancerSemantic proximity Read ↗

Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung CancerSemantic proximity Read ↗

Emerging actionable targets to treat therapy-resistant colorectal cancersSemantic proximity Read ↗

FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer CellsSemantic proximity Read ↗

FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.Semantic proximity Read ↗

Cellular mechanisms of acquired drug resistance against regorafenib in colon cancer cellsSemantic proximity Read ↗

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cellsSemantic proximity Read ↗

FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10Semantic proximity Read ↗

Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise UsSemantic proximity Read ↗

Mcl-1 Ubiquitination and DestructionSemantic proximity Read ↗

FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapySemantic proximity Read ↗

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.